Ninlaro® (ixazomib) is an oral prescription medicine used to treat multiple myeloma in combination with the medicines Revlimid® (lenalidomide) and dexamethasone, in people who have received at least one prior treatment. It belongs to a class of drugs known as proteasome inhibitors.

Ninlaro belongs to a class of drugs called proteasome inhibitors. It’s a targeted treatment for multiple myeloma. Ninlaro targets (works on) a specific protein inside myeloma cells. It creates a buildup of protein in the myeloma cells, which causes those cells to die. Ninlaro comes as capsules that are taken by mouth.

Ninlaro is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat multiple myeloma in people who have tried at least one other therapy. Ninlaro is often combined with a corticosteroid and Revlimid to treat myeloma. Ninlaro is also known by its drug name, ixazomib.

Ninlaro (Ixazomib) for the Treatment of Multiple Myeloma Ninlaro (ixazomib) is an oral prescription therapy that Takeda developed to treat multiple myeloma. Doctors prescribe it in combination with Revlimid (lenalidomide) and the corticosteroid dexamethasone for people with myeloma who have undergone at least one prior treatment.

Ninlaro is a cancer medicine that interferes with the growth and spread of cancer cells in the body. Ninlaro is used in adults to treat multiple myeloma (bone marrow cancer), in combination chemotherapy with lenalidomide and dexamethasone. This combination is usually given after treatment with at least one other cancer medicine has failed.